title: Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.
abstract: Serum samples from 2008 human immunodeficiency virus (HIV)-positive and 551 HIV-negative women were tested for immunoglobulin A (IgA) to human papillomavirus (HPV) type 16 capsids. IgA seropositivity was lower than previously reported IgG seropositivity (7% vs. 51%), but, like IgG antibodies, HPV 16 IgA was associated with sexual behavior, cervicovaginal HPV 16 DNA, and cytological abnormalities. IgA seropositivity was higher in HIV-positive women than in HIV-negative women (7.7% vs. 4.9%; P=.02), but the association was lost after adjustment for HPV 16 cervicovaginal infection. IgA, but not IgG, seropositivity was associated with progression to high-grade cytological abnormalities (relative hazard [RH], 2.2 [95% confidence interval, 1.2-4.2]), raising the possibility that an IgA response to HPV 16, as described for other DNA viruses, may be a marker of persistent viral replication. The risk of incident infection with non-16-related HPV types was increased in IgA seropositive women (RH, 1.8 [95% confidence interval, 1.3-2.6]), compared with seronegative women (RH, 2.2 [95% confidence interval, 0.9-5.4]), but there was no difference in the risk of incident HPV 16 or HPV 16-related infections. This may be evidence of partial type-specific or clade-specific immunity conferred by seropositivity to HPV 16 capsids.
authors.affiliation: Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. rviscid1@jhem.jhmi.edu
authors.forename: Raphael P
authors.initials: RP
authors.lastname: Viscidi
authors.forename: Linda
authors.initials: L
authors.lastname: Ahdieh-Grant
authors.forename: Michael F
authors.initials: MF
authors.lastname: Schneider
authors.forename: Barbara
authors.initials: B
authors.lastname: Clayman
authors.forename: L Stewart
authors.initials: LS
authors.lastname: Massad
authors.forename: Kathryn M
authors.initials: KM
authors.lastname: Anastos
authors.forename: Robert D
authors.initials: RD
authors.lastname: Burk
authors.forename: Howard
authors.initials: H
authors.lastname: Minkoff
authors.forename: Joel
authors.initials: J
authors.lastname: Palefsky
authors.forename: Alexandra
authors.initials: A
authors.lastname: Levine
authors.forename: Howard
authors.initials: H
authors.lastname: Strickler
mesh_terms: D000914:Antibodies, Viral / Q000097:blood*; D002213:Capsid / Q000276:immunology; D002584:Cervix Uteri / Q000473:pathology / Q000821:virology; D015331:Cohort Studies; D016001:Confidence Intervals; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood*; D007074:Immunoglobulin G / Q000097:blood; D016017:Odds Ratio; D027383:Papillomaviridae / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000150:complications* / Q000473:pathology / Q000821:virology; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D014481:United States; D014621:Vagina / Q000473:pathology / Q000821:virology; D014626:Vaginal Smears
chemical_list: D000914:Antibodies, Viral; D004279:DNA, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G